Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).

9615 Background: Rolapitant is a novel NK-1 receptor antagonist with a half-life of 180h, and does not inhibit CYP3A4 as other drugs do in the class, and therefore requires no dose modifications of concomitant steroids. Rolapitant demonstrated efficacy for prevention of CINV in phase 3 trials (HEC1, HEC2, and MEC). This pooled analysis examined the effect of rolapitant on QoL. Methods: In 3 double-blind, active-controlled studies, pts were randomized to oral rolapitant 200 mg or placebo 1–2 h before chemotherapy. All pts received active control: granisetron 2 mg oral or 10 mcg/kg IV and oral dexamethasone 20 mg. In the MEC study, granisetron was continued on Days 2 and 3. QoLwas assessed on Day 6 using the Functional Living Index-Emesis (FLIE) Questionnaire, and reported as a total score and by nausea and vomiting domains. Pts with a valid questionnaire from the MITT population (all randomized pts who received at least 1 dose of study drug) in the 2 pooled HEC studies and one MEC study were analyzed. Resu...